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ARTICLE
Two high-risk susceptibility loci at 6p25.3 and
14q32.13 for Waldenström macroglobulinemia
Mary L. McMaster et al.#
Waldenström macroglobulinemia (WM)/lymphoplasmacytic lymphoma (LPL) is a rare,
chronic B-cell lymphoma with high heritability. We conduct a two-stage genome-wide
association study of WM/LPL in 530 unrelated cases and 4362 controls of European
ancestry and identify two high-risk loci associated with WM/LPL at 6p25.3 (rs116446171,
near EXOC2 and IRF4; OR= 21.14, 95% CI: 14.40–31.03, P= 1.36 × 10−54) and 14q32.13
(rs117410836, near TCL1; OR= 4.90, 95% CI: 3.45–6.96, P= 8.75 × 10−19). Both risk alleles
are observed at a low frequency among controls (~2–3%) and occur in excess in affected
cases within families. In silico data suggest that rs116446171 may have functional importance,
and in functional studies, we demonstrate increased reporter transcription and proliferation in
cells transduced with the 6p25.3 risk allele. Although further studies are needed to fully
elucidate underlying biological mechanisms, together these loci explain 4% of the familial risk
and provide insights into genetic susceptibility to this malignancy.
DOI: 10.1038/s41467-018-06541-2 OPEN
Correspondence and requests for materials should be addressed to M.L.M. (email: Mary.McMaster@nih.hhs.gov). #A full list of authors and their afﬂiations
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aldenström macroglobulinemia (WM) is a subset of
lymphoplasmacytic lymphoma (LPL) characterized by
the presence of an immunoglobulin type M (IgM)
monoclonal gammopathy1. Together, WM/LPL account for 2% of
all non-Hodgkin lymphoma, with an estimated 2330 new cases
diagnosed per year in the US2. Family history of WM/LPL or
related lymphoproliferative disorder is strongly associated with
WM/LPL risk3,4. Autoimmunity and select infections are also
associated with WM/LPL risk5–8, and limited data suggest a
possible relationship with certain lifestyle and occupational fac-
tors8, but overall little is known about its etiology. A somatic
driver mutation, MYD88 p.L265P, occurs in most cases of WM9.
However, germline MYD88 (myeloid differentiation primary
response 88) mutations have not been observed, and despite early
promising ﬁndings by linkage analysis10, no predisposing gene
mutations have been conclusively reported to date. Characterizing
the genetic factors inﬂuencing susceptibility to WM/LPL is an
important step toward understanding its etiology. To discover
genetic loci for WM/LPL susceptibility, we perform a two-stage
genome-wide association study (GWAS) of WM/LPL, leveraging
a family-based oversampling approach in the discovery followed
by replication in an independent, predominantly non-familial,
cohort. Here we report new susceptibility loci at 6p25.3 and
14q32.13 for WM/LPL and provide insights into the genetic
etiology of this distinctive B-cell lymphoma.
Results
Discovery population, genotyping, and analysis. Oversampling
cases with a family history of hematological malignancy, we geno-
typed 244 WM/LPL cases of European descent (Supplementary
Table 1), including 98 unrelated cases (40%) from high-risk families,
using the Illumina OmniExpress SNP microarray chip and selected
controls previously genotyped on the OmniExpress or Omni2.511,12.
Following application of rigorous quality-control metrics, data for
603,492 SNPs with minor allele frequency (MAF) >1% in 217
unrelated cases and 3798 controls of European ancestry remained
for analysis (Methods, Supplementary Table 2). A quantile–quantile
plot of the association results with genotyped SNPs, adjusted for age,
sex, and principal components, revealed enrichment of small P-
values based on a log-additive genetic model and a small degree of
over-dispersion (lambda= 1.05), consistent with other GWAS and
due in part to possible polygenic effects13 (Supplementary Fig. 1a).
Several SNPs at chromosome 6p25.3 reached genome-wide sig-
niﬁcance with P-values between 1.22 × 10−8 and 5.64 × 10−20
(Supplementary Fig. 2a).
To reﬁne the association signal and identify other regions
potentially associated with risk, we imputed common SNPs using
the Haplotype Reference Consortium panel14. Following imputa-
tion and association testing (Supplementary Fig. 1b), the
strongest association at 6p25.3 was rs116446171 (P= 1.59 ×
10−48; information score= 0.9985; Supplementary Fig. 2b), a
well-imputed SNP between EXOC2 (Exocyst complex component
2, also known as Sec5) and IRF4 (Interferon regulatory factor 4).
A second SNP, rs76106586, was highly signiﬁcant and in strong
linkage disequilibrium (LD; r2= 1.0) with rs116446171. Although
other SNPs appeared to be strongly associated with risk,
conditional association analyses suggest a single signal accounted
for the association in this region (Supplementary Table 3). SNPs
at chromosome 14q32.13 also reached genome-wide signiﬁcance,
and conditional analyses suggest there may be more than one
independent signal at 14q32.13 (Supplementary Fig. 2b; Supple-
mentary Tables 4, 5).
Independent replication without familial enrichment. Eleven
SNPs (Supplementary Table 6) with P ≤ 5 × 10−6 in the discovery
analyses were selected for de novo replication in an additional 313
WM/LPL cases, with 24 (8%) reporting a positive family history,
and 564 controls of European ancestry (Supplementary Tables 1,
2). The combined analysis of 530 WM/LPL cases and 4362
controls conﬁrmed two distinct loci at chromosome 6p25.3
(rs116446171; odds ratio (OR)= 21.14, 95% conﬁdence interval
(CI)= 14.40–31.03, P= 1.36 × 10−54) and 14q32.13
(rs117410836, OR= 4.90, 95% CI= 3.45–6.96, P= 8.75 × 10−19),
as shown in Table 1 and Fig. 1. Both SNPs were well-imputed in
the discovery (information scores >0.96), and technical validation
using Taqman or Sanger sequencing showed >99% concordance
between imputed and genotyped calls for both SNPs (Supple-
mentary Table 7). The SNPs were genotyped using two different
genotyping platforms in the replication, suggesting that our
results are not due to platform artifact. Although the effect esti-
mates were attenuated in the replication, suggesting some inﬂa-
tion due to winner’s curse and/or oversampling of familial cases
in the discovery, both SNPs replicated with highly statistically
signiﬁcant P-values (P= 2.54 × 10−13 and 1.16 × 10−5 for
rs116446171 and rs117410836, respectively; Table 1). The effects
were similar when the analysis was limited to WM cases
(rs116446171: OR= 24.41, 95% CI= 16.46–36.23, P= 7.43 ×
10−57; rs117410836: OR= 5.14, 95% CI= 3.56–7.43, P= 2.78 ×
10−18; Supplementary Table 6). A suggestive second independent
signal was observed at 14q32.13 with a directly genotyped SNP
(rs179159, r2= 0.002, P= 4.66 × 10−7; Supplementary Table 6),
which was slightly attenuated after conditioning on rs117410836
(P= 3.16 × 10−6). No other locus replicated.
Risk-variant enrichment in WM/LPL families and heritability.
To assess whether the risk variants occurred at a higher than
expected frequency within high-risk families, we genotyped the
two loci in available affected relatives of familial cases. In families
in which the index case had the rs116446171 risk variant, 76% of
ﬁrst-degree relatives with WM or its precursor, IgM monoclonal
gammopathy of undetermined signiﬁcance (MGUS), also carried
the risk variant (Supplementary Table 8). Similarly, in families in
which the index case had the rs117410836 risk variant, 86% of
ﬁrst-degree relatives with WM or IgM MGUS also carried the risk
variant. In both instances, the risk variant frequency in affected
relatives exceeded the expected 50% distribution (Pbinomial= 0.01
for rs116446171 and Pbinomial= 0.03 for rs117410836), which is
consistent with theoretical models of familial co-segregation15.
Exploration of heritability in a broader sense, using effect esti-
mated from the replication, indicated that these two loci explain
4% of the familial risk for WM/LPL. When we explored the
potential contribution of all common variants to the heritability,
we estimated that common SNPs could explain ~25% (95% CI=
15.4–34.5%) of the heritability as a whole, suggesting more
common loci are likely to be discovered with larger sample sizes.
Functional annotation of rs116446171. rs116446171 is located
679 base pairs (bp) downstream of the 3′ untranslated region
(UTR) of EXOC2, in a region bounded proximally by IRF4 and
DUSP22 (Dual speciﬁcity phosphatase 22) and distally by EXOC2
(Fig. 2a). To determine whether rs116446171 might be a func-
tional susceptibility variant, we performed in silico analyses that
indicated the SNP is located in a region overlapping enhancer
histone marks, histone H3 lysine 4 mono-methylation
(H3K4me1) and lysine 27 acetylation (H3K27ac), in B-
lymphoblastoid cell lines (Supplementary Fig. 3). Analysis of
promoter capture Hi-C data16 showed that this region interacts
with the IRF4 and, to a lesser extent, DUSP22 promoters in naïve
and total primary B-cells (Supplementary Fig. 3), consistent with
reports of long-range enhancer-promoter interactions17,18. In
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silico analyses indicated that the rs116446171 (C) allele (“wild
type”) is a predicted binding site for microRNA (miR) miR-378a-
5p, and the single-nucleotide change from wild type (C) to risk
(G) variant converts the nucleotide sequence to a binding site for
a different miR, miR-324-3p (Fig. 2b).
No evidence for signiﬁcant cis-eQTLs (expression quantitative
trait loci) within Epstein-Barr virus (EBV)-transformed lympho-
cytes or whole blood was observed from analysis of Genotype-
Tissue Expression Project (GTEx) data (Supplementary Table 9).
rs116446171 is not located within the 3′UTR of the annotated
transcript of EXOC2; however, alternative cleavage and polyadeny-
lation has known capability to alter the length of 3′UTR regions19.
Cell-type-speciﬁc polyadenylation occurs in the immunoglobulin
locus and mature B-cells, resulting in transcript isoforms that lead
to changes in protein structure20. Therefore, we explored in silico
data for evidence for an extended UTR for EXOC2 (Supplementary
Fig. 4). Based on published 3′ end-sequencing data performed by
various groups20–22, we found evidence that rs116446171 could be
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Fig. 1 Regional association plots of two SNPs associated with the risk of WM/LPL. a Chromosome 6p25.3 (rs116446171) and b chromosome 14q32.13
(rs117410836). Shown are the −log10 association P-values from the discovery log-additive genetic model for all SNPs in the region (dots) and combined
discovery and replication ﬁxed-effects analysis (diamonds). The lead SNPs are shown in purple, with results from both the discovery (small diamonds) and
combined (large diamonds) analyses. Estimated recombination rates (from 1000 Genomes) are plotted in blue. The SNPs surrounding the most signiﬁcant
SNP are color-coded to reﬂect their correlation with this SNP. Pairwise r2 values are from 1000 Genomes European data. Locations of recombination
hotspots are depicted by peaks corresponding to the rate of recombination. Genes, position of exons and direction of exons and direction of transcription
from UCSC genome browser (http://genome.ucsc.edu) are denoted. Plots were generated using LocusZoom (http://csg.sph.umich.edu/locuszoom)
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an enhancer in normal and malignant B-cells as well as other cell
types. We then determined whether the SNP can cause changes to
the secondary structure of the RNA of EXOC2, using RNAfold
Webserver23 to predict in silico the centroid model with minimum
free energy structures and base pair probabilities in the region
surrounding rs116446171. As shown in Supplementary Fig. 5, the
risk variant is predicted to induce a bulge in the region compared to
the other variant. Data from cBioPortal24 and COSMIC25 for the
closest gene, EXOC2, indicated a low frequency of somatic
mutations in hematopoietic and lymphoid tissues, suggesting that
occurrence of age-dependent clonal somatic mosaicism is unlikely
to account for our results.
In vitro functional evaluation of rs116446171. To further
explore the functional role of the rs116446171 risk variant, we
used an enhanced green ﬂuorescent protein (EGFP) reporter
assay to estimate transcript levels. In addition to the pCS-EGFP-
3′G (risk) construct, we also created pCS-EGFP-3′C (wild type,
WT) and pCS-EGFP-3′Δ (null) constructs to use as comparators.
Stably transduced HEK293T cell lines were grown for conducting
the assays. Cells transduced with the risk allele reporter pCS-
EGFP-3′G showed signiﬁcantly increased EGFP ﬂuorescence
compared to the WT, Null, and the commercial EGFP reporters
(Fig. 3a). Quantitative PCR analysis showed signiﬁcantly higher
EGFP mRNA levels in cells harboring the risk variant (Fig. 3b),
possibly resulting from increased transcription or translational
controls such as stability of EGFP mRNA. Furthermore, cells
harboring the Null construct had signiﬁcantly decreased EGFP
mRNA levels, suggesting the deleted segment of DNA harboring
the SNP might have an important role in the self-maintenance of
Table 1 Association statistics for two independent SNP genotypes and WM/LPL risk
Nearest gene SNP Positiona Variant Effb/Oth Stage EAF controls Cases/controls n/n OR (95% CI) P-value
6p25.3
EXOC2 rs116446171 484453 G/C Stage 1 0.0191 217/3798 56.44 (32.89, 96.85) 1.59E−48
Stage 2 0.0195 312/564 7.71 (4.46, 13.33) 2.54E−13
Combined 529/4362 21.14 (14.40, 31.03) 1.36E−54
14q32.13
Intergenic rs117410836 96051974 C/T Stage 1 0.0266 217/3798 10.62 (6.17, 18.29) 1.63E−17
Stage 2 0.0355 306/563 2.81 (1.77, 4.45) 1.16E−05
Combined 523/4361 4.90 (3.45, 6.96) 8.75E−19
For stages 1 and 2, P-values were generated using logistic regression. For the combined stage, the odds ratio and P-values were generated using a ﬁxed-effects model controlling for age, gender and
genotyping center
WM Waldenström macroglobulinemia, LPL lymphoplasmacytic lymphoma, SNP single-nucleotide polymorphism, Eff effect, Oth other, EAF effect allele frequency, n number, OR odds ratio, CI conﬁdence
interval
aGenome coordinates are from NCBI human genome GRCh37/human genome (hg) build 19
bVariant associated with an effect on risk of WM/LPL
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Fig. 2 Genomic position and alignments of rs116446171 to miRs. a Schematic representation of the position of rs116446171 relative to the 3′UTR of EXOC2
on chromosome 6 and b alignments of rs116446171 wild type and risk variants with the binding sites of microRNAs, miR-378a-5p and miR-324-3p
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transcriptional control of EGFP mRNA. We saw no effect on
EXOC2 transcript levels (Supplementary Fig. 6). Transduced cells
harboring the risk variant showed signiﬁcantly increased cell
proliferation, based on the MTT assay (Methods), compared to
cells transduced with the empty, wild type, or null vectors
(Fig. 3c).
To evaluate the functional effect of the miR-binding site
conversion conferred by the risk variant, we created pre-
microRNA expression plasmids and transfected cells containing
the wild type (C) or risk (G) variant (Methods). Overexpression of
either premiR-378a-5p and premiR-324-3p in cells harboring the
wild type or the risk variant decreased EGFP protein ﬂuorescence
(Fig. 4). However, no miR-speciﬁc effects were observed in the
transfected cells overexpressing miR-378a-5p or miR-324-3p,
respectively (Supplementary Fig. 7), suggesting that the observed
phenotypes in the cells harboring the risk variant might not be due
to direct interference of the miRs with translation.
To further investigate the possible role of the miR-324-3p
binding site created by the risk variant, we cloned 2, 4, or 8
tandem repeats of the 25-base pair (bp) sequence centered around
rs116446171G/C into the 3′UTR of the EGFP reporter, in both cis
and trans orientations (Methods). We observed a proportional
increase in EGFP mRNA transcript levels (Fig. 5a) and a similar
effect on cellular proliferation (Fig. 5b) from the constructs
incorporating increasing numbers of repeats of the rs116446171
risk variant that appeared to be dose-dependent in cis but, as
expected, not in trans. These data suggest rs116446171 alters a
binding site for miRNA. The miR-324-3p binding site results in
increased gene expression. Previous studies have shown that miRs
can inﬂuence tumorigenesis through various processes26,27. miR-
324-3p induces promoter-mediated expression of RelA, a subunit
of NF-κB (nuclear factor kappa-light-chain-enhancer of activated
B-cells)28, and the NF-κB signaling network is important in the
pathogenesis of B-cell malignancies, including WM29,30. How-
ever, the precise mechanism by which non-canonical miR
binding might increase WM/LPL risk is unclear.
Functional annotation of rs117410836. The most signiﬁcant
SNP marker at 14q32.13 (rs117410836) is located near an
uncharacterized long non-coding RNA (lncRNA; LINC02318),
GLRX5 (glutaredoxin 5), and members of the T-cell leukemia
(TCL) gene family (TCL1A, TCL1B, and TCL6). rs117410836
resides in a repressive chromatin domain with histone H3 lysine
27 trimethylation (H3K27me3) (Supplementary Fig. 3). In silico
analyses using Hi-C data suggest that the region containing a
linked SNP (rs1150666963; r2= 0.75) interacts with the TCL1A
promoter in total primary B-cells (Supplementary Fig. 3;
Methods).
Discussion
In this study, we used a two-stage genome-wide approach to
identify association between genetic variants and the risk of WM/
LPL. We oversampled familial WM/LPL cases to enrich for
potential susceptibility loci in our discovery stage and used an
independent, predominantly non-familial sample to replicate our
results. We found two loci at 6p25.3 and 14q32.13 associated with
WM/LPL risk in individuals of European ancestry.
Deﬁnitive identiﬁcation of the functional variants and genes
remains a major challenge of GWAS. In this study, the most
signiﬁcant SNP, rs116446171 (6p25.3), is identical to that shown
to be highly associated with diffuse large B-cell lymphoma in
European and East Asian populations31,32. While this observation
is congruent with data supporting the co-aggregation of B-cell
disorders, we cannot yet exclude the possibility that another
highly signiﬁcant linked SNP, such as rs76106586, is responsible
for the observed association.
rs116446171 is located in proximity to EXOC2, IRF4, and
DUSP22. These genes and their associated transcriptional pro-
grams have been implicated in a variety of lymphoid cancers33–35
and are plausible WM/LPL susceptibility genes. IRF4 expression
is aberrantly downregulated in WM/LPL36, speciﬁcally in the
plasma cell compartment37. IRF4 has a critical role in plasma cell
differentiation, class-switch recombination, and germinal center
fate decisions38, and negatively regulates Toll-like-receptor (TLR)
signaling by binding MYD8839. DUSP22 modulates immune and
inﬂammatory responses through regulation of MAPK (mitogen-
activated protein kinase) signaling40 and suppresses IL6/STAT3
(interleukin 6/signal transducer and activator of transcription)-
mediated signaling41, an important MYD88-independent
mechanism for WM cell growth and survival42. EXOC2 inter-
acts with Ral (RAS-like proto-oncogene) proteins at the nexus of
viral exposure and host immune response43 and is critical for
cancer cell proliferation, invasion, and metastasis44,45; it also
interacts with NF-κ pathway constituent, TBK1 (TANK binding
kinase 1) to promote tumor cell survival46.
The susceptibility locus at 14q32.13, rs117410836, maps most
closely to the previously uncharacterized lncRNA, LINC02318.
LncRNA regulation of transcription, cytokine production and
other cellular functions has been implicated in cancer47 as well as
in the development and function of the innate immune system.
Speciﬁc lncRNAs inﬂuence gene expression programs, including
the NF-κB signaling pathway48, interact with transcription fac-
tors49, and have been shown to be induced via the canonical TLR
pathway involving MYD88 and NF-κB proteins50. Among TCL
family members in this region, TCL1 has been shown to be
aberrantly expressed in 73% of WM tumor samples51. Dysregu-
lated TCL1 expression in B-cells enhances cell proliferation and
survival, leading to cell transformation and mature B-cell tumors
through multiple effector mechanisms, including NF-κB activa-
tion52–55. Limited data are available regarding genetic variation in
this region56. Thus, additional work is needed to understand the
functional implications of variation at this locus and its rela-
tionship to WM/LPL.
In conclusion, we performed a GWAS of WM/LPL and iden-
tiﬁed two independent loci that are associated with the risk of
WM/LPL with substantially higher than expected estimated odds
ratios for a GWAS of an adult cancer. It is remarkable that the
effect size for 6p25.3 is substantively different for WM/LPL
compared to other subtypes of NHL. The effect size was especially
pronounced in our discovery, where we oversampled familial
cases that are more likely to harbor disease variants, but remained
highly signiﬁcant in a predominantly non-familial replication set.
The large effect size observed for rs116446171 in 6p25.3 near
IRF4, DUSP22, and EXOC2 and preliminary in silico and func-
tional evidence suggest we may have discovered an important
non-coding variant for WM risk. Familial co-segregation analyses
are necessary to understand the implications for familial risk and
any warranted clinical application. Additional functional and
epidemiological studies are needed to clarify underlying biological
mechanisms and to identify additional susceptibility loci that may
inﬂuence disease risk.
Methods
Study approval. Each participating study obtained written informed consent from
all participants and approval from its respective human subjects review committee,
as follows: CPS-II: Emory University Institutional Review Board; ENGELA:
IRB00003888—Comité d’Évaluation Ethique de l’Inserm IRB #1; EPIC: Imperial
College London; EpiLymph: International Agency for Research on Cancer; HPFS:
Harvard TH Chan School of Public Health Institutional Review Board; Iowa-Mayo
SPORE: University of Iowa and Mayo Clinic Institutional Review Board; Mayo CC:
Mayo Clinic Institutional Review Board; MSKCC: Memorial Sloan-Kettering
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Cancer Center Institutional Review Board; NCI Family: NCI Clinical Center
Institutional Review Board; NCI-SEER: NCI Special Studies Institutional Review
Board; NHS: Partners Institutional Review Board/Brigham and Women’s Hospital;
NSW: NSW Cancer Council Ethics Committee; PLCO, NCI Special Studies
Institutional Review Board; SCALE: Scientiﬁc Ethics Committee for the Capital
Region of Denmark and Regional Ethical Review Board in Stockholm (Section 4)
IRB#5; UCSF2: University of California San Francisco Committee on Human
Research; WHI: Fred Hutchinson Cancer Research Center Institutional Review
Board; Yale: Human Investigation Committee, Yale University School of Medicine
(See Supplementary Table 1 for study abbreviations).
Phenotype deﬁnition. LPL was deﬁned according to World Health Organization
(WHO)1,57 criteria. WM was deﬁned according to WHO1,57 and required the
presence of both an LPL inﬁltrate in the bone marrow together with a monoclonal
immunoglobulin type M (IgM) protein in the serum. In cases where histopatho-
logic criteria for LPL were met but serum protein electrophoresis data were not
available, the case was classiﬁed as LPL. Diagnoses were validated for all cases by
medical and pathology reports. All cases were unrelated. Family history of WM/
LPL or other B-cell malignancy (i.e., chronic lymphocytic leukemia (CLL), other
non-Hodgkin lymphoma (NHL), Hodgkin lymphoma, or multiple myeloma) was
ascertained by self-report, and positive family history was validated in a subset
(83%).
Discovery population. Cases for the stage 1 discovery analysis included 207
participants in a WM family study at the National Cancer Institute (NCI Family)7
and 37 cases identiﬁed through a case–control study of NHL and CLL at the Mayo
Clinic (Mayo CC). The 244 stage 1 cases included 98 reporting a family history of
WM/LPL (n= 42) or other B-cell malignancy (n= 56), 118 cases reporting no
family history, and 28 cases with unknown family history. Stage 1 controls (n=
3812) were obtained from a previous GWAS of NHL11 and included 987
lymphoma-free controls from four US-based studies (National Cancer Institute—
Surveillance, Epidemiology, and End Results Interdisciplinary Case-Control Study
of Non-Hodgkin lymphoma (NCI-SEER); the Women’s Health Initiative (WHI);
a population-based case–control study in Connecticut women (Yale); and Mayo
CC) and 2825 cancer-free controls from a study of prostate cancer in the Prostate,
Lung, Colon, and Ovarian (PLCO) Cancer Screening Trial12 (Supplementary
Table 1). Characteristics of the discovery population are shown in Supplementary
Table 2.
Discovery genotyping and quality control. All WM/LPL cases with sufﬁcient
DNA (n= 244) were genotyped on the Illumina OmniExpress SNP microarray
chip at the NCI Cancer Genomics Research Laboratory (CGR). Genotypes were
called using Illumina GenomeStudio software, and rigorous quality control metrics
were employed to ensure that the resulting data were of high quality (Supple-
mentary Table 10). All data analyses and management were conducted
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Fig. 3 The rs116446171 variants affect reporter activity and cell proliferation. a EGFP reporter activity in HEK293T stably transduced cell lines. Cells
transduced with the risk variant (G) showed signiﬁcantly increased ﬂuorescence levels of EGFP compared to the cell lines transduced with the wild type
(WT, (C); P= 0.012). Cells transduced with the Null (Δ) had decreased EGFP ﬂuorescence (P= 0.054, n= 14), and cells transduced with the commercial
3′UTR of EXOC2 showed signiﬁcantly decreased EGFP ﬂuorescence (P < 0.0001, n= 14). Data are expressed as mean fold change relative to the cells
transduced with the vector, ±standard error of the mean (s.e.m.), n= 14 replicates. **P < 0.01, ****P < 0.0001. b Quantitative PCR analysis of EGFP
transcripts in HEK293T stably transduced cell lines. Signiﬁcant changes of EGFP mRNA levels were detected in cells harboring the variant allele compared
to the cells harboring the wild-type allele (P= 0.031). Cells harboring the Null allele had reduced EGFP transcripts levels (P= 0.036). Data are expressed
as mean % change relative to the endogenous controls, ±s.e.m., n= 9 replicates for each experiment. *P < 0.05. c Proliferation assay of cells harboring
rs116446171, the deletion (Null) of an 18-bp segment centered on rs116446171, and the commercial 3′UTR reporter. The cell line transduced with the
variant allele showed signiﬁcantly increased cell proliferation compared to the cell lines transduced with the EXOC2 3′UTR, the WT and the Null. Data are
expressed as mean fold change of the cell line in the day seeded, ±s.e.m., n= 9 replicates. ****P < 0.0001. All P-values were calculated with unpaired t-test
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using Genotyping Library and Utilities (GLU), version 1.0 (http://code.google.com/
p/glu-genetics/). Speciﬁcally, we excluded 15 subjects at this step due to: samples
with a call rate of ≤95% (7 cases); insufﬁcient phenotype data (5 cases); and
unexpected duplicates (>99.9% concordance; 2 cases, 1 control). Quality control
duplicates had >99.9% concordance. Genotype data from the controls were pre-
viously generated using the Illumina OmniExpress (Mayo CC, NCI-SEER, WHI,
Yale) and the Illumina Omni2.5 (PLCO) chips and underwent the same quality
control parameters as cases11,12. We assessed ancestry using a set of population
informative SNPs58 and data from the HapMap CEU, YRI, and ASA populations.
We estimated admixture coefﬁcients for each sample using the GLU v1.0 struct.
admix module based on the method by Pritchard et al.59 and using HapMap60 data
as the ﬁxed reference populations. Participants with <80% European ancestry were
excluded (4 cases, 9 controls; Supplementary Fig. 8). One member of each related
pair known to be within three degrees of relatedness by inspection of the pedigree
or with estimated pihat >0.4 was excluded (9 cases, 4 controls). After exclusions, all
pairwise pihat estimates were <0.08 for cases, and 217 cases and 3798 controls
remained for analysis (Supplementary Table 10). For the analysis, SNPs with call
rate <95%, Hardy–Weinberg equilibrium P < 1 × 10−6, minor allele frequency
(MAF) < 1%, or previously shown to be analytically uninformative were excluded,
yielding 603,492 autosomal SNPs for analysis. To evaluate population substructure,
we performed a principal components analysis using the GLU v1.0 struc.pca
module, which is comparable to EIGENSTRAT61. Plots of the ﬁrst 5 principal
components are shown in Supplementary Fig. 9. We conducted initial association
testing assuming a log-additive genetic model, adjusting for age, sex, and two
principal components that were found to be signiﬁcant in the null model.
Imputation of variants. To allow us to evaluate the genome more comprehen-
sively for SNPs associated with WM, we imputed SNPs in the stage 1 discovery
GWAS using the Michigan Imputation Server (https://imputationserver.sph.umich.
edu/index.html) and the Haplotype Reference Consortium (HRCr1) panel (https://
www.sanger.ac.uk/science/collaboration/haplotype-reference-consortium)14 fol-
lowing pre-phasing using SHAPEIT (https://mathgen.stats.ox.ac.uk/
genetics_software/shapeit/shapeit.html#home). For imputation, SNPs with MAF <
1% were not excluded. Association testing on the imputed data was conducted
using the Frequentist association module in SNPTEST v.2.5.2 (https://mathgen.
stats.ox.ac.uk/genetics_software/snptest/snptest.html), assuming dosages for the
genotypes, a log-additive model, and adjusting for age, sex and two signiﬁcant
principal components. Tested SNPs with MAF ﬁlter <2.5% for cases and <1% for
controls or with SNPTEST INFO score ﬁlter <0.3 were excluded, resulting in
6,440,053 autosomal SNPs.
Replication population. An independent stage 2 replication population included
313 WM/LPL cases from the NCI Family study (n= 29), Mayo CC/Iowa-Mayo
SPORE (n= 105), Memorial Sloan Kettering Lymphoproliferative Disorders Study
(MSKCC)62 (n= 64), and ten additional studies11,12 (Supplementary Table 1).
Among these 313 cases, 24 had a family history of a hematologic malignancy and
105 reported no family history; family history information was reported as
unknown or was unavailable for the remainder. The stage 2 controls (n= 564)
were obtained from Mayo CC/Iowa-Mayo SPORE (n= 167), MSKCC (n= 302),
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Fig. 5 Dose-dependent effect of rs116446171 variants on reporter
transcription and cell proliferation. a Quantitative PCR analysis of EGFP
transcripts in stably transduced cells with tandem repeats of the
rs116446171 variant allele. The variant allele was inserted within the EXOC2
3′UTR region as a single copy or as two, four and eight repeats in either cis
or trans orientation. Data are expressed as mean fold change of the
endogenous controls, ±s.e.m., n= 9 replicates. ****P < 0.0001.
b Proliferation assay of cells transduced with tandem repeats of the variant
allele. Cells harboring eight tandem repeats proliferate signiﬁcantly faster
than cells harboring four tandem repeats, and cells harboring four tandem
repeats proliferate signiﬁcantly faster than cells harboring two or one
repeat. Data are expressed as mean fold change of the cell line in the day
seeded, ±s.e.m., n= 9 replicates. ****P < 0.0001. All P-values were
calculated with unpaired t-test
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and eight other studies11,12 (Supplementary Table 1). Characteristics of the repli-
cation population are shown in Supplementary Table 2.
SNP selection for replication. After ranking the SNPs by P-value and ﬁltering for
linkage disequilibrium (LD; r2 < 0.05), we selected eleven SNPs from the most
promising loci identiﬁed in stage 1 after imputation with P < 5 × 10−6 (Supple-
mentary Table 6) for de novo replication in an independent sample of 313 WM/
LPL unrelated cases and 564 controls. We chose the most signiﬁcant imputed and
genotyped SNPs at our two top loci (chromosome 6p25.3 and chromosome
14q32.13) and, whenever possible, the most signiﬁcant SNP (genotyped or impu-
ted) for additional promising loci with P < 1 × 10−6 in the discovery. Imputed SNPs
with an information score ≤0.75 were excluded. Furthermore, only SNPs with
MAF > 1% were selected for replication, and no SNPs proceeded to replication if
they occurred in regions where they appeared as singletons or obvious artifacts. Of
the 11 SNPs selected for replication, ﬁve were directly genotyped and the remaining
six were imputed in the discovery.
Replication genotyping and analysis. We conducted genotyping on independent
case–control sets in three centers using custom genotyping assays developed for
either TaqMan (Applied Biosystems; validated at the NCI CGR) or Sequenom
(Sequenom Laboratories; validated at the Mayo Clinic and MSKCC), or Sanger
sequencing (for a single SNP, rs117410836, for which a custom TaqMan assay
could not be designed). Genotyping was performed by the NCI CGR, the Mayo
Clinic and MSKCC and included duplicates for quality control. Following exclu-
sions for genotyping failures and self-reported non-European ancestry, data for 313
cases and 564 controls remained for analysis (Supplementary Table 10). Associa-
tion testing was conducted assuming a log-additive model, adjusting for age, sex,
Ashkenazi ancestry, and genotyping center, which appeared to be an appropriate
model for the top SNPs (Supplementary Table 11). The results from the discovery
and replication were then combined using a ﬁxed-effects meta-analysis method
with inverse variance weighting based on the estimates and standard error from
each stage.
Technical validation. Technical validation was conducted for all SNPs taken
forward for replication on a subset of cases (n= 213) and controls (n= 478) from
the discovery. Comparing genotype calls from Taqman assays or Sanger sequen-
cing with genotyped or imputed data from the GWAS showed high concordance
(>97%) for all SNPs. Concordance for both genome-wide signiﬁcant SNPs
(rs116446171 and rs117410836) and the secondary signal at chromosome 14
(rs179159) was >99% (Supplementary Table 7).
Assessment of enrichment among high-risk families. Of the 122 WM/LPL cases
in this study reporting a family history, 100 were enrolled in a family study of WM.
Among these cases, 21 had the risk variant at rs116446171 or rs117410836 and at
least one living relative diagnosed with a relevant B-cell disorder and DNA
available for genotyping. To assess whether the risk variants occurred at a higher
frequency than expected within high-risk families, we genotyped available affected
relatives using the Illumina OmniExpress. After employing rigorous quality control
metrics, genotype data were available for 58 relatives, including 32 ﬁrst-degree
relatives and 14 more distantly related relatives with WM, IgM MGUS, or other
lymphoproliferative disorders (Supplementary Table 8). For index cases carrying
the effect variant at either locus, we computed the frequency with which their
affected relatives carried the same effect variant and used the binomial test to
determine whether the frequency was greater than expected under the assumption
that 50% of ﬁrst-degree relatives would share the same variant.
Heritability analysis. To estimate the familial risk explained by these loci for WM/
LPL, we estimated the contribution of each independent SNP to the heritability
using the equation h2SNP= β22ƒ(1− ƒ), where β is the log-odds ratio per copy of
the risk allele from the replication stage analyses and ƒ is the allele frequency, and
summed the contributions of all novel SNPs63. We then estimated the total her-
itability based on the estimated relative risks= 24.0 and 20.0 in ﬁrst-degree rela-
tives for WM and WM/LPL, respectively, from Kristinsson et al.3 using the
equation derived by Pharoah and colleagues64. We calculated the proportion of
familial risk explained by dividing the summed contributions of the novel SNPs by
the total heritability. To estimate the contribution of all common SNPs to familial
risk, we used the method proposed by Yang et al.65, which was adapted to
dichotomous traits66 and implemented in the Genome-wide Complex Trait Ana-
lysis (GCTA) software (cnsgenomics.com/software/gcta/). The genetic similarity
matrix was estimated from our discovery scan using all genotyped autosomal SNPs
with a minor allele frequency >0.01. We used restricted maximum likelihood
(REML), the default option for GCTA, to ﬁt the appropriate variance components
model, assuming the lifetime risk of WM was 0.00003 to estimate heritability on a
liability scale. We then transformed the obtained estimate into a sibling relative risk
estimate and estimated the percentage of familial risk explained.
Functional annotation of rs116446171. To explore whether the rs116446171 SNP
was encompassed within EXOC2 transcripts in any cell type, we analyzed published
data from Poly(A)site (http://www.polyasite.unibas.ch/), an annotation tool build
using a total of over 400 million reads from 78 3′end sequencing libraries generated
with standard 3′ end-sequencing protocols22. Poly(A) sites are annotated based on
the protein-coding genes and long non-coding RNAs (lncRNAs) contained in the
UCSC Basic Table of GENCODE V19. The original data and experimental
methods are described by Lianoglou21. We analyzed data from the Genotype-
Tissue Expression (GTEx) Project (https://www.gtexportal.org/home/) from whole
blood, lymphocytes, and EBV-transformed lymphoblastoid cells to determine the
presence of cis expression quantitative trait loci (eQTLs), adjusted for principal
components. We explored possible effects of variation at rs116446171 on sec-
ondary RNA structure using RNAfold Server (http://rna.tbi.univie.ac.at/cgi-bin/
RNAWebSuite/RNAfold.cgi), a thermodynamic structure prediction tool that
predicts secondary minimum free energy structures and base pair probabilities
from single RNA or DNA sequences23. In parallel, these SNPs were compared to a
collection of internally processed epigenetic data sets. Model-based analysis of
ChIP-Seq (MACS) package67 was used to identify H3K4me1, H3K4me3, and
H3K27ac peaks from GSE50893 ChIP-seq data68. Reference epigenome data was
from the Roadmap Epigenomics Project (http://www.roadmapepigenomics.org);
other ChIP-seq and DNase-seq data were from the ENCODE project (https://www.
encodeproject.org). Signal tracks (reads per million) were generated using a 200-
base pair (bp) sliding window and a step size of 20 bp. To determine potential SNP-
gene promoter interactions, we used Capture Hi-C (http://promoter.bx.psu.edu/hi-
c/view.php), a method for proﬁling chromosomal interactions involving targeted
regions of interest, such as gene promoters, globally and at high resolution. We
used promoter Capture Hi-C data in 17 primary hematopoietic cell types23.
Regions showing signiﬁcant chromatin interactions with CHiCAGO (http://
regulatorygenomicsgroup.org/chicago) scores ≥5 were downloaded from https://
osf.io/u8tzp/.
Selection of SNP for functional evaluation. Our main ﬁnding, rs116446171, is
located 679 bp downstream of the 3′UTR of the EXOC2 gene. Although it is not
predicted to be contained in any EXOC2 transcript, we chose to further evaluate
this SNP for possible functional relevance based on (1) prior evidence that this
rs116446171 is also the most signiﬁcant SNP associated with diffuse large B-cell
lymphoma31,32; (2) the unusually large observed effect size on WM/LPL risk; (3) in
silico evidence suggesting an association with regulatory elements in primary B-
cells and the lymphoblastoid cell line, GM12878; and (4) the observation that the
risk variant might affect a predicted miRNA binding site.
Cell culture and generation of stable cell lines. HEK293T cells were used
because of their reliable growth and transfection proﬁle and suitability for gene
expression analysis. HEK293T cells were obtained from American Type Culture
Collection (293T ATCC® CRL-3216™; ATCC, Manassas, VA), where they were
authenticated by Short Tandem Repeat (STR) proﬁling. The cells were maintained
under standard cell culture conditions at 37 °C in 5% CO2 in a humid environment.
The culture medium, DMEM, was purchased from Mediatech Inc. (Manassas, VA)
and supplemented with 10% FBS from Gemini Bio Products (West Sacramento,
CA). Plasmocin Prophylactic (InvivoGen, San Diego, CA) was used in the culture
medium to prevent mycoplasma contamination. Lentiviruses were produced by
transfection of HEK293T packaging cells with a three plasmid system69. To gen-
erate stable cell lines, HEK293T cells were seeded into 6-well plates for 24 h before
infection with 5 multiplicity of infection (moi) of lentivirus in OptiMEM (Invi-
trogen; ThermoFisher Scientiﬁc, Waltham, MA) in the presence of 8 μg/mL
polybrene (Sigma-Aldrich, Inc., St. Louis, MO). After the incubation, medium was
replaced with fresh DMEM with 10% FBS for another 24 h before selection in
medium containing 1 µg/mL of puromycin, until the control cells were no longer
viable. All the stably transduced cell lines were subsequently maintained in medium
supplemented with 0.5 µg/mL of puromycin during experimentation.
Plasmids and site-speciﬁc mutagenesis. The EXOC2 3′UTR Lenti-reporter-GFP
(green ﬂuorescent protein) vector was purchased from Applied Biological Materials
Inc. (Richmond, BC, Canada Catalog # MT-h57118). To construct the reporter
plasmids with the extended EXOC2 3′UTR containing the wild type, variant and
deleted sequence (Supplementary Fig. 10a), a wild-type 987 bp fragment PCR-
ampliﬁed with high Fidelity Platinum PCR SuperMix (Invitrogen) (forward 5′-GG
CTTGTCAGGGTTTTCAAG-3′, reverse 5′-CATGCAAAGATGACAAGAGACG
G-3′) from human genomic DNA was ﬁrst cloned into pCRII-TOPO (Invitrogen)
and subsequently fused to the EXOC2 3′UTR Lenti-reporter-GFP vector with
Choo-Choo cloning kit from MCLAB (South San Francisco, CA) to create the
construct pCS-EGFP-3′C. For generation of the variant pCS-EGFP-3′G, PCR
fragments (forward 5′-GTTGTAATTTACTTGACATTTTTCCCT-3′, reverse 5′-G
TTAACTTGCTCCAGCTGCTGGTTT-3′; forward 5′-GTTAACAAACCAGCACC
TGGAGCAA-3′, reverse 5′-GCTGGAAATGAAATGCCACT-3′) were ampliﬁed
with high Fidelity Platinum PCR SuperMix and used to replace the corresponding
wild type fragment with Choo-Choo cloning kit. For generation of the deletion
construct pCS-EGFP-3′Δ, PCR fragment (forward 5′-CTCGTTAACTTCTCTCT
CGGCTTTCATCTAAC-3′, reverse 5′-GCTGGAAATGAAATGCCACT-3′)
was ampliﬁed and replaced the corresponding wild type fragment with Choo-
Choo cloning kit. To construct the empty vector, the commercial EXOC2 3′UTR
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Lenti-reporter-GFP vector was digested with EcoRI and XhoI and re-ligated with
Quick Blunting and Quick Ligation Kits from New England Biolabs (Ipswich, MA).
For generation of the tandem repeats of a 25-bp sequence centered around
rs116446171 C/G inserted into the EcoRI site of the extended EXOC2 3′UTR
(Supplementary Fig. 10b), PCR primers (forward 5′-GTTAACTTGCTCCAGGT
GCTGGTTT-3′, reverse 5′-GTTAACAAACCAGCACCTGGAGCAA-3′) were
annealed and ligated into pCRII-TOPO with Quick Blunting and Quick Ligation
Kits from New England Biolabs. Following digestion with EcoRI, fragments con-
sisting of different tandem repeats were inserted into the EcoRI site of the EXOC2
3′UTR. All the clones with cis or trans orientation and various copy numbers of the
tandem repeats were conﬁrmed by sequencing performed by the Heﬂin Center for
Genomic Sciences, University of Alabama at Birmingham.
Expression and normalization of pre-microRNAs. PremiR-378a-5p (Cat # mir-
p227) and PremiR-324-3p (Cat # mir-p193) were expressed in self-inactivated
(SIN) lentiviral, pLV-miR vectors purchased from BIOSETTA (San Diego, CA).
The control vector (pLV13) was created by insertion of a 118-bp random sequence
into the XhoI site of the pLV-miR vector (re-ligation of mir-p227 after deletion of
the XhoI fragment containing the insert of miR-378a); 4 copies of the tandem
repeats in cis-orientation were inserted into the XhoI site of the pLV-miRNA
vector, which served as a locker plasmid (pLV18). All vectors express a rPuro (red
ﬂuorescent puromycin-N-acetyl-transferase) gene and the measurement of the red
ﬂuorescence in cell lines after transfection can be used for normalization. Cells
were transfected with the above constructs using lipofectamine to determine the
effects of the microRNAs on the EGF reporter. The EGFP ﬂuorescence was
measured and normalized against transfection efﬁciencies in the same cell lines
with different microRNA plasmids and normalized against the genomic copy
number of EGFP among cell lines transduced with WT, Variant, Null, 3′UTR of
EXOC2 and vectors.
Cell proliferation assay. Live cells were enumerated at wavelength 570 nm using
the MTT assay of mitochondrial enzymatic activity (CellTiter 96 Non-Radioactive
Cell Proliferation Assay, Promega Corp., Madison, WI).
Real-time quantitative RT-PCR. Total RNA was extracted using the RNeasy Mini
Kit (Qiagen, Louisville, KY) with on-column DNase digestion. Reverse transcrip-
tion was performed with Accupower CycleScript RT Premix (Bioneer, Alameda,
CA). Real-time quantitative PCR reactions were performed using SYBR green PCR
Master Mix from Bio-Rad (Hercules, CA) with EXOC2 primer (forward 5′-GAT
CCTTCAGCTCATGCACA-3′, reverse 5′-GACTGAGATGGCCCAACACT-3′)
and EGFP primer (forward 5′-CAAGATCCGCCACAACATCG-3′, reverse 5′-GA
CTGGGTGCTCAGGTAGTG-3′). Triplicate reactions for the genes of interest and
4 endogenous controls (ACTB, B2M, GAPDH, and GUSB) were performed
separately on the same cDNA samples by using CFX Connect Real-Time System
(Bio-Rad). Proprietary primer sets for ACTB, B2M, GAPDH, and GUSB were
purchased from RealTimePrimers, LLC (https://www.realtimeprimers.com/). The
mean cycle threshold (Ct) was used for the ΔΔCt computations of the relative
transcript abundance.
Normalization for transduction efﬁciencies of cell lines. Genomic DNAs were
puriﬁed with Quick-DNA Universal Kit (Zymo Research). Real-time quantitative
PCR was performed using SYBR green PCR Master Mix with 3 sets of EGFP
primer (Set I: forward 5′-CTTCTTCAAGTCCGCCATG-3′, reverse 5′-ATGTGAT
CGCGCTTCTCGTT-3′; Set II: forward 5′-CGTAAACGGCCACAAGTTCA-3′,
reverse 5′-CTTCATGTGGTCGGGGTAGC-3′; Set III forward 5′-CAAGATCCG
CCACAACATCG-3′, reverse 5′-GACTGGGTGCTCAGGTAGTG-3′), while
GAPDH was used for the reference gene (Set I: forward 5′-CCCTTCATTGAC
CTCAACTACATGGT-3′, reverse 5′-GAGGGGCCATCCACAGTCTTCTG-3′; Set
II: forward 5′-GTGAAGGTCGGAGTCAACG-3′, reverse 5′-TGAGGTCAATGA
AGGGGTC-3′). The ratio of copy number of the integrated reporter gene in cell
lines was calculated against the reference gene GAPDH.
Direct measurement of EGFP and rPuro ﬂuorescence. EGFP and rPuro ﬂuor-
escence were measured directly with 6-well plates with or without Triton X-100
(1%) treatment using Synergy H1 Hybrid Reader (BioTek, Winooski, VT) Gen5
Microplate Reader and Imager Software (ex/em for GFP: 485/519 nm; for rPuro:
553/593 nm). Fluorescence measurements were performed using the bottom optic,
orbital averaging with 2 mm diameter and 20 ﬂashes per well. All the cell lines were
cultured in the phenol red free DMEM media (Mediatech, Corning, NY) supplied
with 10% FBS to lower the background. All measurements were background
subtracted (HEK293T cells with no plasmid transfection) and normalized against
the genomic copy number of the EGFP genes.
In silico miR-binding site prediction. miRBase (http://www.mirbase.org/search.
shtml) homologous search with the wild type rs116446171 sequence detected
signiﬁcant homology with the mature microRNA, miR-378a-5p.
rs116446171 sequence with a single C to G change eliminates that homology, and
instead creates a new homology with the mature microRNA, miR-324-3p.
Statistical analysis for functional experiments. All the experimental data from
cell viability and proliferation assays, EGFP reporter assay, and quantitative PCR
analysis were performed by the unpaired t-test and ﬁtted with an exponential
growth equation of Prism 6 for Windows from GraphPad Software (San Diego
CA). Data are shown as means ± the standard error of the mean (s.e.m.) of values
obtained for n replicates as indicated in the ﬁgure legends.
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Data availability
The genotyping dataset generated during this study has been deposited in the dbGaP
repository with the accession code phs001284.v1.p1. All other relevant data generated for
this study are available upon request from the authors.
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